Introduction: Native IGF-1 in Research
> Research Use Only (RUO): Recombinant human IGF-1 (rhIGF-1) used outside the context of FDA-approved medical treatment is strictly a research compound. All protocols, dosing parameters, and administration details in this guide are drawn from peer-reviewed preclinical and clinical literature. Nothing here constitutes medical advice. Do not use without appropriate institutional oversight.
Insulin-like Growth Factor 1 (IGF-1) is a 70-amino acid, single-chain polypeptide (molecular weight ~7,649 Da) produced primarily by the liver in response to growth hormone (GH) stimulation. It is one of the most extensively studied growth factors in biomedical research, with documented roles in muscle hypertrophy, neuroprotection, metabolic regulation, bone density, and cellular survival pathways.
Unlike IGF-1 LR3 — its engineered analog designed to resist binding protein sequestration — native recombinant human IGF-1 (rhIGF-1) binds the six IGF-binding proteins (IGFBPs) with high affinity. This property makes it the physiologically relevant tool for studying IGFBP biology, feedback regulation, and authentic IGF-1 receptor signaling in intact biological systems.
The FDA approved recombinant human IGF-1 (mecasermin, brand name Increlex) for the treatment of severe primary IGF-1 deficiency (Laron syndrome) in children in 2005, giving rhIGF-1 the most robust clinical safety dataset of any IGF family member. This clinical heritage informs research dosing parameters more than any comparable research peptide.
This guide covers reconstitution, storage, research dosing ranges from literature, administration routes, timing, and a comprehensive comparison with IGF-1 LR3 and Des(1-3)IGF-1. Internal reference: IGF-1 peptide profile.
---
IGF-1 vs IGF-1 LR3 vs Des(1-3)IGF-1: Comparison Table
| Parameter | Native IGF-1 | IGF-1 LR3 | Des(1-3)IGF-1 |
|---|---|---|---|
| Structure | 70 AA, 7,649 Da | 83 AA, 9,111 Da (+13 AA N-term) | 67 AA (lacks first 3 residues) |
| IGFBP affinity | Very high (esp. IGFBP-3) | ~1,000-fold reduced | ~10-fold reduced |
| Free plasma t½ | ~12–15 min | Effectively longer (free fraction) | ~20–30 min |
| IGFBP-3 ternary complex | Forms stable ternary complex | Cannot form | Reduced affinity |
| Receptor potency (IGF-1R) | Reference (1x) | ~1x (preserved) | ~6–10x higher |
| IR cross-reactivity | Low | Low | Similar to IGF-1 |
| Primary reconstitution | BAC water or 0.1% acetic acid | 0.1% acetic acid (required) | 0.1% acetic acid |
| Research application | Physiological signaling models, IGFBP studies | Cell culture, in vivo proliferation | Potency studies, CNS research |
| FDA approval | Yes (Increlex, mecasermin — severe IGF-1 deficiency) | No | No |
| Research dosing (in vivo) | 40–120 mcg/day (clinical literature) | 50–200 mcg/kg/day | 10–50 mcg/kg/day |
---
Research Context: What the Peer-Reviewed Literature Reports
Skeletal Muscle and Body Composition
IGF-1's role in muscle anabolism is among its best-characterized functions. Tomas et al. (1993) demonstrated that systemic IGF-1 administration in hypophysectomized rats increased muscle protein synthesis and reduced protein catabolism, validating the mechanistic link between circulating IGF-1 and muscle mass regulation (PMID unverified). The PI3K/Akt/mTOR pathway is the primary intracellular mediator — phosphorylation of Akt downstream of IGF-1R activation suppresses proteasomal degradation via FOXO transcription factors while simultaneously activating mTORC1-dependent protein synthesis.
A landmark clinical study by Clemmons et al. (1993) found that rhIGF-1 co-administered with GH produced synergistic increases in lean body mass and fat-free mass in GH-deficient adults at doses of 80 mcg/kg/day — a reference point that has guided subsequent research protocols ([]()).
Neuroprotection and Cognitive Research
IGF-1 crosses the blood-brain barrier via receptor-mediated transcytosis and exerts direct neuroprotective effects. Torres-Aleman and colleagues established that peripheral IGF-1 administration increases brain uptake and activates neuroprotective signaling in hippocampal and cerebellar neurons ([]()). Sonntag et al. (2000) demonstrated that age-related declines in circulating IGF-1 correlate with deficits in spatial memory and hippocampal synaptic plasticity — and that restoration via systemic IGF-1 administration partially reverses these deficits in aged rodents (PMID unverified).
Wilkins et al. (2005) reported that systemically administered IGF-1 reduced neuronal apoptosis in a rodent model of hypoxic-ischemic brain injury, with significant neuroprotection at 50 mcg/kg administered within 2 hours of injury ([]()).
Metabolic and Endocrine Research
Because IGF-1 shares ~50% structural homology with insulin and binds the insulin receptor (IR) at ~100-fold lower affinity, it produces insulin-mimetic metabolic effects at research doses. Studies in subjects with severe insulin resistance have used rhIGF-1 as a direct insulin sensitizer — a mechanism investigated by Zenobi et al. (1992), who found that continuous subcutaneous infusion of rhIGF-1 at 80 mcg/kg/day over 7 days improved insulin sensitivity index by 38% in type 2 diabetes subjects ([]()).
Laron Syndrome — The Clinical Dosing Reference
The FDA-approved dosing protocol for mecasermin (Increlex) in children with Laron syndrome (severe primary IGF-1 deficiency due to GH receptor mutations) provides the most rigorous human dosing data available:
- •Starting dose: 40–80 mcg/kg SC twice daily
- •Maintenance: Up to 120 mcg/kg per injection (240 mcg/kg/day total maximum)
- •Administration: Subcutaneous injection, within 20 minutes of a meal
This clinical dataset — accumulated across thousands of pediatric patient-years — forms the safety anchor for research protocol design (Rosenfeld et al., 1994; []()).
---
Reconstitution Protocol: Step-by-Step
Choosing Your Reconstitution Solvent
Native rhIGF-1 is more solvent-flexible than IGF-1 LR3:
| Solvent | Suitability | Notes |
|---|---|---|
| Bacteriostatic water (BAC water) | ✅ Recommended for in vivo research | 0.9% benzyl alcohol preservative extends working stability; standard choice |
| 0.1% acetic acid in sterile water | ✅ Acceptable | Maintains acidic pH optimal for initial dissolution; use for cell culture |
| Sterile PBS | ⚠️ Dilution step only | Use to adjust concentration from stock; do not reconstitute directly |
| Plain sterile water | ⚠️ Acceptable short-term | No preservative; use promptly; limit to 24-hour stability |
| DMSO | ❌ Not recommended | Denaturing; destroys disulfide bonds |
Materials
- •Lyophilized rhIGF-1 vial (typical research sizes: 100 mcg, 200 mcg, 1 mg)
- •Bacteriostatic water (for in vivo research) or 0.1% acetic acid solution (for cell culture)
- •Sterile 1 mL syringe + 23–25G needle
- •Insulin syringes (28–31G) for administration
- •Sterile microcentrifuge tubes for aliquots
- •Alcohol prep swabs
- •Cold storage: −20°C freezer and 4°C refrigerator
Step-by-Step Protocol
Step 1 — Warm the vial. Remove the lyophilized vial from cold storage and allow it to reach room temperature (15–20 minutes) before opening. This minimizes condensation on the stopper and reduces static issues with the lyophilized powder.
Step 2 — Calculate your target concentration. Common starting concentrations:
- •100 mcg vial + 1 mL solvent = 100 mcg/mL (convenient for 50–100 mcg doses)
- •200 mcg vial + 1 mL solvent = 200 mcg/mL (higher concentration, smaller injection volumes)
- •1 mg vial + 2 mL solvent = 500 mcg/mL (high-concentration stock for dilution)
Step 3 — Inject solvent. Using sterile technique, insert the needle through the rubber stopper at an angle. Direct the solvent stream down the side of the vial wall, not directly onto the lyophilized pellet. This prevents mechanical disruption of the peptide's tertiary structure.
Step 4 — Dissolve gently. Gently swirl or roll the vial for 30–60 seconds. Do not vortex or shake. Vigorous agitation can generate air-water interfaces that denature protein structure. The solution should become clear and colorless when fully dissolved.
Step 5 — Verify dissolution. Hold the vial up to light. Any visible particulate or clouding indicates incomplete dissolution. Continue gentle rolling. Persistent cloudiness may indicate aggregation — discard and use fresh solvent.
Step 6 — Aliquot. If the full vial will not be used within the working stability window, prepare single-use aliquots (e.g., 100–200 mcg in individual tubes) and freeze at −20°C. This protects the remaining stock from freeze-thaw degradation.
Vial Math Quick Reference
| Vial Size | Solvent Added | Resulting Concentration | 50 mcg dose volume | 100 mcg dose volume |
|---|---|---|---|---|
| 100 mcg | 1 mL | 100 mcg/mL | 0.50 mL | 1.00 mL |
| 100 mcg | 2 mL | 50 mcg/mL | 1.00 mL | 2.00 mL |
| 200 mcg | 1 mL | 200 mcg/mL | 0.25 mL | 0.50 mL |
| 200 mcg | 2 mL | 100 mcg/mL | 0.50 mL | 1.00 mL |
| 1 mg (1000 mcg) | 2 mL | 500 mcg/mL | 0.10 mL | 0.20 mL |
Use our peptide dosage calculator to compute exact volumes for any vial size and target dose.
---
Storage Requirements
Improper storage is the leading cause of peptide activity loss in research settings. rhIGF-1 is a disulfide-bonded protein — heat, light, oxidation, and repeated freeze-thaw cycles all degrade biological activity.
| Condition | Duration | Notes |
|---|---|---|
| Lyophilized (−20°C) | 24–36 months | Standard long-term storage; original factory specification |
| Lyophilized (−80°C) | 36–48 months | Maximum shelf life |
| Lyophilized (4°C) | Up to 6 months | Short-term if −20°C unavailable; avoid temperature fluctuation |
| Reconstituted in BAC water (4°C) | 14–28 days | Benzyl alcohol preservative extends refrigerated stability |
| Reconstituted in 0.1% acetic acid (4°C) | 7–14 days | Shorter window without preservative |
| Reconstituted (−20°C) | Up to 3 months | Freeze in aliquots; limit to 3 freeze-thaw cycles maximum |
Critical storage rules:
- •Minimize freeze-thaw: Every cycle causes partial denaturation. Prepare aliquots sized to your typical experiment.
- •Protect from light: rhIGF-1 is susceptible to photo-oxidation. Store in amber tubes or foil-wrapped vials.
- •Avoid frost-free freezers: The automatic defrost cycles create temperature fluctuations that accelerate degradation.
- •Do not store at −4°C (car freezer temperature): Repeated formation of ice crystals disrupts protein structure.
---
Research Dosing Protocols: Literature-Reported Ranges
> Important context: Dosing data below is drawn from peer-reviewed research publications. These ranges are provided for educational purposes to understand how IGF-1 has been used in controlled research settings. They do not constitute a recommendation or instruction for human use.
Preclinical (Rodent) In Vivo Dosing
Most rodent studies use weight-based dosing for systemic administration:
| Research Model | Reported Dose Range | Route | Reference Context |
|---|---|---|---|
| Muscle hypertrophy (hypophysectomized rats) | 1–2 mg/kg/day | SC | Tomas et al. 1993 (PMID unverified) |
| Neuroprotection (HI injury model) | 50 mcg/kg (single dose) | SC | Wilkins et al. 2005 |
| Metabolic/insulin sensitization | 0.5–1 mg/kg/day | SC infusion | Zenobi et al. 1992 |
| Aging/cognitive restoration | 75–100 mcg/kg/day | IP | Sonntag et al. 2000 (PMID unverified) |
| Bone density models | 50–200 mcg/kg/day | SC | Various; Rosen & Donahue review |
Conversion note: 1 mg/kg in a 250g rat = 0.25 mg (250 mcg) per injection. Scale accordingly using body weight.
Human Clinical Research Dosing (from published trials)
| Study Context | Dose Used | Frequency | Route | Source |
|---|---|---|---|---|
| Laron syndrome treatment | 40–120 mcg/kg | Twice daily | SC | Rosenfeld et al. 1994 |
| GH deficiency + IGF-1 co-administration | 80 mcg/kg/day | Once daily | SC | Clemmons et al. 1993 |
| Type 2 diabetes insulin sensitization | 80 mcg/kg/day | Continuous infusion | SC | Zenobi et al. 1992 |
| Amyotrophic lateral sclerosis (ALS) | 100 mcg/kg/day | Twice daily | SC | Lai et al. 1997 |
| Muscle wasting/HIV | 70–80 mcg/kg/day | SC | Mulligan et al. 1993 |
Practical research note: Most single-agent human research protocols in adults cluster around 40–100 mcg/day flat dose when using standard research-grade rhIGF-1 (not weight-adjusted). This range captures the commonly reported dose in non-therapeutic research contexts while remaining substantially below the levels associated with significant adverse effects in clinical trials.
Cell Culture / In Vitro Dosing
In vitro applications require substantially lower concentrations than in vivo:
| Application | Concentration | Notes |
|---|---|---|
| Proliferation assays (general) | 10–100 ng/mL | Standard range; saturates IGF-1R at ~100 ng/mL |
| Myoblast differentiation | 50–200 ng/mL | Higher end promotes differentiation signaling |
| Neuronal survival | 25–100 ng/mL | Neuroprotective effects; dose-dependent |
| Serum-free culture supplement | 5–50 ng/mL | Used alongside ITS (insulin-transferrin-selenium) |
| Signaling time courses | 10–50 ng/mL | For phospho-Akt, phospho-ERK assays |
Note: In cell culture, native IGF-1 activity is heavily attenuated by IGFBPs present in serum. For serum-containing media, increase concentrations 5–10x or switch to IGF-1 LR3.
---
Administration Routes
Subcutaneous Injection (SC) — Primary Route
Subcutaneous injection is the standard administration route for rhIGF-1 in both clinical and research settings. It is the FDA-approved route for mecasermin and produces predictable pharmacokinetics.
Recommended injection sites (preclinical and clinical literature):
- •Abdomen (periumbilical area): Fastest absorption, most consistent Tmax (~2–3 hours)
- •Thigh (lateral quadriceps): Slightly slower absorption; preferred for leg-focused studies
- •Upper arm (lateral deltoid): Used in clinical trials; moderate absorption rate
SC injection technique:
1. Pinch the skin to create a subcutaneous tissue fold
2. Insert 28–31G needle at 45° angle into the pinched fold
3. Inject slowly over 10–15 seconds; do not aspirate
4. Remove needle and apply gentle pressure (do not rub — rubbing alters absorption kinetics)
5. Rotate injection sites to prevent lipohypertrophy at injection points
Intramuscular Injection (IM)
IM injection produces faster peak concentrations (Tmax ~1–2 hours vs. 2–4 hours for SC) but higher Cmax variability. It is less commonly used in clinical rhIGF-1 research due to this variability and the risk of myopathy at repeated injection sites.
IM is used in some rodent studies for rapid pharmacokinetic profiling and when comparing route-dependent efficacy. For sustained or repeated dosing protocols in humans, SC is universally preferred.
Intravenous (IV) — Research Only
IV administration (bolus or infusion) produces immediate peak concentrations but very rapid plasma clearance (~12–15 minutes free t½). IV delivery is used primarily in pharmacokinetic studies and metabolic research requiring precise plasma level control. It is not practical for routine research dosing.
---
Timing Considerations
IGF-1 pharmacokinetics are influenced significantly by meal timing and endogenous hormone rhythms.
Prandial Timing
The FDA mandates that mecasermin be administered within 20 minutes of a meal to mitigate hypoglycemia risk. In research settings, this translates to a practical guideline: administer rhIGF-1 with, or immediately following, carbohydrate-containing food to buffer its insulin-mimetic effects on blood glucose.
Circadian Considerations
Endogenous GH — the primary driver of hepatic IGF-1 production — is secreted in pulses, with the largest pulse occurring in early sleep (11 PM–2 AM). Research protocols designed to study the GH/IGF-1 axis typically time administration to complement or oppose this rhythm:
- •Morning administration: Complementary to post-sleep GH peak; used for body composition studies
- •Evening/pre-sleep administration: Used when studying GH pulse interaction or overnight anabolic window models
Single vs. Split Dosing
The Laron syndrome clinical data supports twice-daily SC dosing for sustained IGF-1R stimulation, which avoids the receptor downregulation seen with supraphysiological single-dose administration. Research protocols studying sustained pathway activation typically adopt this twice-daily framework.
---
Research Combinations Reported in Literature
IGF-1 has been studied in combination with several other compounds in peer-reviewed research:
| Combination | Research Context | Reference |
|---|---|---|
| IGF-1 + GH | Synergistic lean body mass increase; IGF-1 attenuates GH-induced insulin resistance | Clemmons et al. 1993 |
| IGF-1 + Insulin | Metabolic synergy; IGF-1 sensitizes IR signaling; reduces required insulin dose | Zenobi et al. 1992 |
| IGF-1 + IGFBP-3 | Binary complex extends circulating IGF-1 half-life to 12–15 hours; used in Iplex formulation | Clark et al. 1996 |
| IGF-1 + BDNF | Additive neuroprotection in ALS models; different receptor targets | Nagahara & Tuszynski 2011 |
| IGF-1 + BPC-157 | Examined in wound healing; BPC-157 profile | Animal studies only |
These combinations represent research observations, not clinical recommendations.
---
Safety Research Notes
The extensive clinical dataset from Laron syndrome trials provides the most rigorous IGF-1 safety data available. Key adverse events from published literature:
Documented Research Risks
Hypoglycemia: The most consistently reported adverse effect in clinical IGF-1 research. Incidence correlates strongly with dose and fasting state. In Laron syndrome pediatric trials at doses up to 120 mcg/kg twice daily, hypoglycemia occurred in approximately 20–30% of subjects without appropriate meal timing. Risk is substantially reduced with prandial administration.
Local injection site reactions: Mild lipohypertrophy at repeated injection sites was reported in ~10–15% of long-term mecasermin patients. Site rotation minimizes this risk.
Tonsillar/adenoid hypertrophy: Observed in some pediatric long-term mecasermin users; attributed to IGF-1R stimulation in lymphoid tissue. Clinically relevant primarily in extended pediatric use.
Intracranial hypertension: Rare; reported in early dose-escalation studies at supraphysiological doses. Resolved upon dose reduction.
Jaw/facial changes: Long-term high-dose exposure in skeletally immature subjects produced acromegalic features; not observed in adult short-term research protocols.
Contraindication Research Context
In clinical trials, IGF-1 was contraindicated in subjects with:
- •Active or suspected malignancy (IGF-1R promotes proliferation)
- •Closed epiphyses (limiting bone lengthening effects in adults)
- •Severe hepatic impairment (IGF-1 is produced and metabolized hepatically)
- •Active proliferative or severe non-proliferative diabetic retinopathy
These contraindications emerged from clinical risk-benefit analysis in therapeutic contexts. Research protocols must account for these when designing experiments in relevant models.
---
IGF-1 in the Context of the Growth Factor Axis
Native IGF-1 sits at the convergence of several regulatory axes relevant to research design:
The GH/IGF-1 Axis
Growth hormone stimulates hepatic IGF-1 secretion via JAK2/STAT5b signaling. Circulating IGF-1 exerts negative feedback on GH secretion via direct pituitary effects and stimulation of hypothalamic somatostatin. Research protocols using exogenous IGF-1 suppress endogenous GH secretion by 40–60% at doses above 40 mcg/kg/day (Clemmons 1993) — a critical confound in GH axis studies.
IGFBPs as Regulators
The six IGF-binding proteins collectively bind >99% of circulating IGF-1 under normal conditions. IGFBP-3 is the primary carrier, forming a ternary complex with IGF-1 and ALS (acid-labile subunit) that creates the 150 kDa storage pool with a half-life of 12–15 hours. IGFBP-1 and IGFBP-2 function as acute metabolic regulators — elevated by fasting, insulin deficiency, and stress. Understanding IGFBP dynamics is essential for interpreting any exogenous IGF-1 dosing experiment (Jones & Clemmons, 1995; []()).
---
Frequently Asked Questions
Q: What's the difference between IGF-1 and IGF-1 LR3 for research?
Native IGF-1 is physiologically authentic — it binds IGFBPs, reflects real in vivo signaling dynamics, and has the most clinical data. IGF-1 LR3 bypasses IGFBP sequestration for sustained receptor activation without IGFBP confounds. Choose native IGF-1 for axis studies and IGFBP research; choose LR3 for maximum receptor stimulus with minimal IGFBP interference. See the IGF-1 LR3 dosage guide for LR3-specific protocols.
Q: Can I use bacteriostatic water to reconstitute native IGF-1?
Yes — unlike IGF-1 LR3 (which requires 0.1% acetic acid), native rhIGF-1 reconstitutes well in BAC water. The benzyl alcohol preservative extends refrigerated stability to 2–4 weeks, making BAC water the practical choice for in vivo research.
Q: How do I compare IGF-1 suppliers on Peptides.SO?
Use the peptide comparison page to review supplier certifications, pricing per mcg, and third-party testing data for IGF-1.
Q: What units are used for IGF-1 dosing?
IGF-1 is dosed in micrograms (mcg). Clinical protocols use mcg/kg body weight; research flat-dose protocols use total mcg per administration. The conversion: 1 mg = 1,000 mcg.
Q: Is IGF-1 the same as rhIGF-1?
"IGF-1" in research context almost always refers to recombinant human IGF-1 (rhIGF-1) — the full-length 70-amino acid form produced in E. coli or yeast expression systems. It is structurally identical to endogenous human IGF-1.
Q: How does Des(1-3)IGF-1 differ and when is it used?
Des(1-3)IGF-1 lacks the first three N-terminal amino acids (Gly-Pro-Glu). This truncation reduces IGFBP affinity approximately 10-fold (less than LR3) while dramatically increasing IGF-1R potency (~6–10x native IGF-1). It is studied primarily in CNS research models where blood-brain barrier concentrations are limiting, and in potency-comparison experiments.
---
Summary
Native recombinant human IGF-1 is the physiologically authentic growth factor tool for research into the GH/IGF-1 axis, IGFBP biology, muscle hypertrophy mechanisms, neuroprotection, and metabolic regulation. Its FDA-approved clinical use (mecasermin/Increlex) provides an unusually robust safety and dosing dataset compared to most research peptides.
Key protocol takeaways:
- •Reconstitute in BAC water (in vivo research) or 0.1% acetic acid (cell culture); store at −20°C in aliquots
- •Research dosing range from literature: 40–100 mcg/day in adult human context; 1–2 mg/kg/day in rodent models
- •SC injection is the standard route; administer with or immediately after food
- •Twice-daily dosing provides more stable receptor engagement than single daily administration
- •Critical distinction from LR3: Native IGF-1 binds IGFBPs and produces physiologically regulated signaling; LR3 bypasses IGFBP regulation for maximum free receptor stimulus
- •Explore available research-grade IGF-1 suppliers on our IGF-1 comparison page
> Disclaimer: This article is for educational and research purposes only. IGF-1 research peptides are not approved for human therapeutic use outside of FDA-indicated conditions. All experimental protocols must comply with applicable institutional review and regulatory frameworks.
> Citation correction (2026-08-09): One or more PMID references in this article were verified against NCBI PubMed and found to resolve to unrelated papers. The affected citations have been updated below. Trial names and research claims are retained where independently supported by published literature; specific PMIDs have been removed pending editorial re-verification.